|
Min Zhong, Fang-Cheng Cai
Chongqing, China
Author Affiliations: Department of Neurology, Children's Hospital of Chongqing Medical University, Chongqing 400014, China (Zhong M, Cai FC)
Corresponding Author: Fang-Cheng Cai, MD, Department of Neurology, Children's Hospital of Chongqing Medical University, Chongqing 400014, China (Tel: 86-23-63622544; Fax: 86-23-63622874; Email: caifangc@126.com)
Background: This article aims to review recent advances in the etiology, typing, pathogenesis and treatment of Guillain-Barr¨¦ syndrome (GBS).
Data sources: Articles were searched in PubMed with the searching items related with Guillain-Barr¨¦ syndrome.
Results and Conclusion: The commonly identified preceding pathogens have been identified such as Campylobacter jejuni, cytomegalovirus and others. Immunomodulating treatment has been proven to alleviate nerve damage and shorten the progression of the disease. GBS remains a serious disorder with a relatively high disability rate and a mortality, which definitely requires more effective treatment.
Key words: Guillain-Barr¨¦ syndrome; infection; neuropathy; Immunomodulating treatment World J Pediatr 2007;3(3):187-194
|
